期刊文献+

胃肠间质瘤诊治的发展历程与方向 被引量:3

原文传递
导出
摘要 人们对胃肠间质瘤(gastrointestinal stromal tumor, GIST)的认知过程被认为是实体瘤发展的成功典范,从病理形态学的发现到蛋白水平的鉴别,再至关键分子机制的破解,最后针对特异分子靶点药物的研发,这一历经近百年的研究历程奠定了目前对GIST成功诊治的基础。现简述GIST诊治的发展历程并对其未来的发展方向做初步探讨。
作者 李健
出处 《中国普外基础与临床杂志》 CAS 2017年第2期137-140,共4页 Chinese Journal of Bases and Clinics In General Surgery
  • 相关文献

参考文献1

二级参考文献18

  • 1Joensuu H,Fletcher C,Dimitrijevic S,Silberman S,Roberts P, Demetri G. Management of malignant gastrointestinal stro-mal tumours. Lancet Oncol 2002; 3: 655-664.
  • 2Tosoni A,Nicolardi L,Brandes AA. Current clinical man-agement of gastrointestinal stromal tumors. Expert Rev Anti-cancer Ther 2004; 4: 595-605.
  • 3van Oosterom AT,Judson I,Verweij J,Stroobants S,Donato di Paola E,Dimitrijevic S,Martens M,Webb A,Sciot R,Van Glabbeke M,Silberman S,Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tu-mours: a phase I study. Lancet 2001; 358: 1421-1423.
  • 4Demetri GD,von Mehren M,Blanke CD,Van den Abbeele AD,Eisenberg B,Roberts PJ,Heinrich MC,Tuveson DA, Singer S,Janicek M,Fletcher JA,Silverman SG,Silberman SL,Capdeville R,Kiese B,Peng B,Dimitrijevic S,Druker BJ, Corless C,Fletcher CD,Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tu-mors. N Engl J Med 2002; 347: 472-480.
  • 5Verweij J,Casali PG,Zalcberg J,LeCesne A,Reichardt P, Blay JY,Issels R,van Oosterom A,Hogendoorn PC,Van Glabbeke M,Bertulli R,Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
  • 6Blanke CD,Rankin C,Demetri GD,Ryan CW,von Mehren M,Benjamin RS,Raymond AK,Bramwell VH,Baker LH, Maki RG,Tanaka M,Hecht JR,Heinrich MC,Fletcher CD, Crowley JJ,Borden EC. Phase III randomized,intergroup tri-al assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
  • 7Zalcberg JR,Verweij J,Casali PG,Le Cesne A,Reichardt P, Blay JY,Schlemmer M,Van Glabbeke M,Brown M,Judson IR. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
  • 8Heinrich MC,Corless CL,Demetri GD,Blanke CD,von Mehren M,Joensuu H,McGreevey LS,Chen CJ,Van den Abbeele AD,Druker BJ,Kiese B,Eisenberg B,Roberts PJ, Singer S,Fletcher CD,Silberman S,Dimitrijevic S,Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21: 4342-4349.
  • 9Patel S,Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 2008; 44: 501-509.
  • 10Demetri GD,Huang X,Garrett CR,Sch ffski P,Blackstein ME,Shah MH. Novel statistical analysis of long-term sur-vival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. Proceedings of the 44th American Society of Clinical Oncology Annual Meeting; May 30-June 03; Chicago: Ameri-can Society of Clinical Oncology,2008: 10524.

共引文献34

同被引文献32

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部